The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Li, Yan; Huang, Qingying; Zhou, Yaoyao; He, Meizhi; Chen, Jianhong; Gao, Yubo; Wang, Xue

doi:10.3389/fphar.2018.01494

Cited by 33 publications

(35 citation statements)

References 50 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis involving 13 studies showed that a high PD-L1 expression could predict a shorter OS (HR = 1.57, 95% CI = 1.09–2.27, P < 0.00001) and poorer DFS (HR = 2.07, 95% CI = 1.20–3.58, P = 0.009) in hepatocellular carcinoma (15). Another study also demonstrated a significant association of PD-L1 expression with a poor biochemical recurrence-free survival (BCR-FS) (HR = 1.78; 95% CI = 1.39 to 2.27; p < 0.00001) in prostate cancer (46). Wang et al showed an association of PD-L1 expression with a poor OS in RCC (47).…”

Section: Discussionmentioning

confidence: 92%

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

et al. 2019

View full text Add to dashboard Cite

Background: The prognostic value of programmed cell death ligand-1 (PD-L1) in patients with nasopharyngeal carcinoma (NPC) remains controversial. Therefore, we conducted this meta-analysis to understand the role of PD-L1 in NPC.Method: We searched PubMed, Embase, Web of Science, and Cochrane Library up to April 2019. We determined the pooled hazard ratio (HR) and 95% confidence intervals (CIs) to assess the relationship between PD-L1 and various survival outcomes. Begg's funnel plot was used to assess any publication bias.Results: Eleven studies involving 1,315 patients were included in this meta-analysis. For overall survival (OS), the HR was 1.48 and 95% CI was 1.00–2.18 (p = 0.049). For disease-free survival (DFS), the HR was 1.51 and 95% CI was 0.85–2.69 (p = 0.162). For distant metastasis-free survival (DMFS), the HR was 1.75 and 95% CI was 0.64–4.79 (p = 0.277). For local recurrence-free survival (LRFS), the HR was 0.67 and 95% CI was 0.06–8.16 (p = 0.756). The results of prognosis of PD-L1 and OS were more significant after sensitivity analysis. The pooled odds ratio indicated that PD-L1 expression was not associated with T stage, N stage, M stage, overall stage, sex, age, smoking, or alcohol intake. No publication bias was found.Conclusion: Our meta-analysis showed that PD-L1 overexpression in NPC was associated with a poor OS and may be useful as a novel prognostic factor for NPC.

show abstract

Section: Discussionmentioning

confidence: 92%

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Additionally, Ni’s study also reported the expression of PD-L1 was positively correlated with the lymph node metastasis in colorectal cancer [29]. The prognostic value was also presented in other solid malignancies including prostate cancer [30], esophageal squamous cell carcinoma [31], glioma [32], Osteosarcoma [33], and non-small cell lung cancer [34]. The results of the present meta-analysis were in line with the results of other types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

Liu

et al. 2019

Cancer Cell Int

View full text Add to dashboard Cite

Background Programmed cell death ligand 1 (PD-L1) expression has been shown to associate with poor prognosis in a variety of solid tumors. However, the prognostic value of PD-L1 expression in cervical cancer is still controversial. Therefore, we carried a meta-analysis to investigate the prognostic and clinicopathological impact of PD-L1 in cervical cancer. Methods A comprehensive literature search in was performed in PubMed, Embase, Web of Science, and Cochrane Library. The correlation between PD-L1 expression and overall survival (OS), progression-free survival (PFS), and clinicopathological features was analyzed by hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). Results Seven studies with 783 patients were included in this meta-analysis. The combined HR and 95% CI of OS was 2.52 (1.09–5.83), p = 0.031. The pooled results for PFS were HR = 2.07, 95% CI = 0.52–8.23, p = 0.302. The results of subgroup analysis showed that PD-L1 was a significant prognostic factor of poor OS in Asian patients (HR = 4.77, 95% CI = 3.02–7.54, p < 0.001) and of poor PFS in Asian patients (HR = 4.78, 95% CI = 1.77–12.91, p = 0.002). However, the pooled results suggested that PD-L1 was not significantly correlated with lymph node metastasis, tumor size, FIGO stage, depth of invasion, lymph-vascular invasion, or age. Conclusions The results of this meta-analysis suggest that PD-L1 overexpression is related to poor OS in patients with cervical cancer and poor PFS in Asian patients with cervical cancer. This study also suggests that PD-L1 is a promising prognostic indicator for cervical cancer.

show abstract

“…SPOP mutation compromises of ubiquitin-mediated PD-L1 degradation leading to increased PD-L1 levels and reduced numbers of infiltrating lymphocytes in prostate cancers [125]. Another recent study showed that phosphorylated RB inhibits NF-kB activation and PD-L1 expression: in patients samples phosphorylated RB inversely correlates with PD-L1 levels [397]. Interestingly, the expression of a phosphorylation-mimetic peptide in prostate cancer cells suppresses radiotherapy-induced upregulation of PD-L1 and augments the therapeutic efficacy of radiation in vivo [397].…”

Section: Sensitivity Of Prostate Cancer To Immunotherapymentioning

confidence: 99%

Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

2019

View full text Add to dashboard Cite

Prostate cancer is the most frequent nonskin cancer and second most common cause of cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with many patients exhibiting an aggressive disease with progression, metastasis, and other patients showing an indolent disease with low tendency to progression. Three stages of development of human prostate tumors have been identified: intraepithelial neoplasia, adenocarcinoma androgen-dependent, and adenocarcinoma androgen-independent or castration-resistant. Advances in molecular technologies have provided a very rapid progress in our understanding of the genomic events responsible for the initial development and progression of prostate cancer. These studies have shown that prostate cancer genome displays a relatively low mutation rate compared with other cancers and few chromosomal loss or gains. The ensemble of these molecular studies has led to suggest the existence of two main molecular groups of prostate cancers: one characterized by the presence of ERG rearrangements (~50% of prostate cancers harbor recurrent gene fusions involving ETS transcription factors, fusing the 5′ untranslated region of the androgen-regulated gene TMPRSS2 to nearly the coding sequence of the ETS family transcription factor ERG) and features of chemoplexy (complex gene rearrangements developing from a coordinated and simultaneous molecular event), and a second one characterized by the absence of ERG rearrangements and by the frequent mutations in the E3 ubiquitin ligase adapter SPOP and/or deletion of CDH1, a chromatin remodeling factor, and interchromosomal rearrangements and SPOP mutations are early events during prostate cancer development. During disease progression, genomic and epigenomic abnormalities accrued and converged on prostate cancer pathways, leading to a highly heterogeneous transcriptomic landscape, characterized by a hyperactive androgen receptor signaling axis.

show abstract

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Cited by 33 publications

References 50 publications

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer

Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

Contact Info

Product

Resources

About